Clear All
12482 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00173-0447-02 00173-0447 Ondansetron Hydrochloride Zofran 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb 11, 1993 Aug 21, 2013 No Longer Used
68788-9670-03 68788-9670 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jul 24, 2013 In Use
55700-0672-30 55700-0672 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sep 14, 2018 Jan 1, 2019 No Longer Used
63323-0318-01 63323-0318 GRANISETRON HYDROCHLORIDE Granisetron 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Nov 20, 2009 In Use
00641-6078-01 00641-6078 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec 26, 2006 In Use
43063-0560-10 43063-0560 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb 12, 2015 Jan 18, 2021 No Longer Used
55390-0250-10 55390-0250 Granisetron Hydrochloride Granisetron Hydrochloride Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Jul 28, 2008 Nov 30, 2009 No Longer Used
52125-0983-52 52125-0983 Ondansetron Hydrochloride Ondansetron Hydrochloride Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jul 7, 2014 Apr 12, 2016 No Longer Used
00078-1098-94 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
00078-1098-30 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
00078-1091-94 00078-1091 asciminib SCEMBLIX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
00078-1091-20 00078-1091 asciminib SCEMBLIX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
00078-1196-20 00078-1196 Asciminib SCEMBLIX 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Apr 18, 2024 In Use
00078-1098-20 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
68727-0712-01 68727-0712 Lurbinectedin ZEPZELCA 0.5 mg/mL Chemotherapy Alkylating Agent Adduct Forming Agent Intravenous Jun 15, 2020 In Use
00015-3080-60 00015-3080 Mitotane Lysodren 500.0 mg/1 Chemotherapy Miscellaneous Agent Adrenal Suppressant Oral Jun 1, 2009 Mar 31, 2021 No Longer Used
00310-9501-95 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Feb 1, 2024 Oct 28, 2024 In Use
00310-9501-04 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Jun 10, 2026 In Use
00310-9501-96 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Oct 23, 2024 In Use
00310-9501-01 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Nov 16, 2023 In Use
00310-9500-01 00310-9500 Capivasertib TRUQAP 160.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Nov 16, 2023 In Use
00310-9500-02 00310-9500 Capivasertib TRUQAP 160.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Oct 18, 2024 In Use
00310-9501-02 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Oct 18, 2024 In Use
00069-8141-20 00069-8141 Crizotinib Xalkori 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Aug 26, 2011 In Use
50242-0130-86 50242-0130 ALECTINIB HYDROCHLORIDE Alecensa 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Oct 10, 2017 In Use

Found 12482 results — Export these results